Beloranib
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
Zafgen · Phase 2 · Completed · Enrollment 17
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| ZGN-440 sterile diluent | Obesity or overweight | n/r | 4 | n/r | n/r |
| 1.2 mg ZGN-440 for injectable suspension | Obesity or overweight | 1.2 mg | 4 | n/r | n/r |
| 1.8 mg ZGN-440 for injectable suspension | Obesity or overweight | 1.8 mg | 4 | n/r | n/r |